Moors & Cabot’s AstraZeneca AZN Stock Holding History

Moors & Cabot’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-250	Closed	-$2K	–	904
2021 Q3	$2K	Buy	+250	New	+$29.1K	﹤0.01%	848

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Moors & Cabot's AZN Position: Q1 2026 in Review

Moors & Cabot increased its AstraZeneca (AZN) stake by 0.73% in Q1 2026, buying an estimated $9.64K and bringing the position to 6,886 shares worth $1.36M. The position accounts for 0.06% of the portfolio, ranked #291.

Moors & Cabot first reported a position in AZN in Q1 2014 and has held it in 49 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Moors & Cabot held 6,886 shares of AstraZeneca worth $1.36M as of Q1 2026.
Moors & Cabot bought 50 AstraZeneca shares in Q1 2026, an estimated $9.64K.
AstraZeneca made up 0.06% of Moors & Cabot's portfolio in Q1 2026, its #291 holding.
Moors & Cabot first reported a position in AstraZeneca in Q1 2014 and has held it in 49 quarters since.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.